ReviewCureus2019
Association of Low Maternal Pregnancy-associated Plasma Protein A with Adverse Perinatal Outcome.
Review in Cureus, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Correlations Between Pregnancy-Associated Plasma Protein A Levels and Pregnancy Characteristics, Placental Volume, Vascularization, and Histopathology.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2026Article
- Altered PAPP-A and Placental Thickness in Pre-Eclampsia and Intrauterine Growth Restriction: A Pilot Study.Journal of clinical medicine · 2026Article
- XGBoost-based analysis of maternal and biochemical factors associated with spontaneous preterm birth: a retrospective cohort study.BMC pregnancy and childbirth · 2025Article
- Clinical value of prenatal screening markers in early pregnancy combined with perinatal characteristics to predict fetal growth restriction.Translational pediatrics · 2024Article
- The role of pregnancy associated plasma protein-A in triple negative breast cancer: a promising target for achieving clinical benefits.Journal of biomedical science · 2024Review
- Article
- Cell-Free Fetal Deoxyribonucleic Acid (cffDNA) Analysis as a Remarkable Method of Non-Invasive Prenatal Screening.Cureus · 2022Review
- PAPPA Expression in Indeterminate Thyroid Nodules as Screening Test to Select Patients for Molecular Testing.International journal of molecular sciences · 2022Article
- Review
- The expression of pregnancy-associated plasma protein-A (PAPP-A) in human blastocoel fluid-conditioned media: a proof of concept study.Journal of assisted reproduction and genetics · 2022Article
- A survey to assess the incidence of Down syndrome risk in rural southwestern Romania.Experimental and therapeutic medicine · 2021Article
- Predictive value of PAPP-A for ectopic pregnancy and analysis of related factors.Experimental and therapeutic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim is to provide an overall view of the association of low pregnancy-associated plasma protein A (PAPP-A) levels with adverse perinatal outcomes. The available literature in PubMed/Medline regarding PAPP-A and adverse pregnancy outcomes was searched for related articles, including terms such as "PAPP-A," "intrauterine growth restriction (IUGR)," "small for gestational age (SGA)," "stillbirth," "adverse outcome," and others. The fifth percentile is supported by many recent studies to be PAPP-A's cutoff for adverse outcome detection and the increased risk seems to be extremely high below 0.2 PAPP-A MoM (multiple of the median). Apart from chromosomal abnormalities, preeclampsia, intrauterine fetal demise, and pregnancy loss have been associated with maternal serum PAPP-A. For results below the first centile, PAPP-A has a strong positive predictive value for SGA and IUGR. Except for its vital role on the cleavage of insulin-like growth factor binding proteins (IGFBP), PAPP-A has proven to be a reliable marker for prenatal screening. Even though PAPP-A as a single predictor proved to be valuable for the prediction of some adverse perinatal outcomes, in some cases, a combination of PAPP-A to other maternal serum markers led to an increase in detection rates. PAPP-A is a promising maternal serum marker for pregnancy outcome prediction with more studies needed in order for its potentials to be fully understood and exploited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.